FRM
ATXS

Fox Run Management’s Astria Therapeutics ATXS Stock Holding History

Fox Run Management’s Portfolio ATXS Stock Details ATXS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-19,957
Closed -$145K – 903
2025
Q3 		$145K Buy
+19,957
New +$135K 0.02% 841
2025
Q2 		– Sell
-34,320
Closed -$183K – 859
2025
Q1 		$183K Buy
+34,320
New +$240K 0.03% 808

Other funds holding ATXS

PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
GCL
Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Fox Run Management's ATXS Position: Q4 2025 in Review

Fox Run Management sold out of Astria Therapeutics (ATXS) in Q4 2025, closing a stake of 19,957 shares — an estimated $145K sold.

Fox Run Management first reported a position in ATXS in Q1 2025 and held it in 2 quarters. The position peaked at $183K in Q1 2025. 141 funds tracked by Wall St. Rank hold ATXS as of Q4 2025.

  • Fox Run Management reported no remaining Astria Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Fox Run Management sold 19,957 Astria Therapeutics shares in Q4 2025, an estimated $145K.
  • Fox Run Management first reported a position in Astria Therapeutics in Q1 2025 and held it in 2 quarters.
  • Fox Run Management's Astria Therapeutics position peaked at $183K in Q1 2025.
  • 141 funds tracked by Wall St. Rank held Astria Therapeutics as of Q4 2025.

Based on Fox Run Management's 13F filing for Q4 2025, filed 11 Feb 2026.